ICS 2019 Scientific Podium Short Oral Session S11 - Male Lower Urinary Tract Symptoms 1

Speakers
	Wednesday 4th September 2019
	16:30 - 18:00
	Hall K Capacity: 1500
	Lunch provided
J Jerzy B Gajewski ICS Chair M Marco H Blanker ICS Chair

16:30

#215 Prevalence and risk factors to develop lower urinary tract symptoms after kidney transplants

Presenter: Alessandro Prudente

Prudente A¹, Gomes Sobrinho D¹, Schwamback G¹, Brito B¹, Gonçalves R¹, Tomaz K¹
1.University of Rondonia
Overactive Bladder, Questionnaire, Voiding Dysfunction , Urgency/Frequency, Nocturia

16:37

#216 Test-retest reproducibility of the Multiple Array Probe Leiden (MAPLe) in men with lower urinary tract symptoms

Presenter: Selma A Goes

Goes S¹, Notenboom-Nas F¹, Knol-de Vries G¹, Witte L², Blanker M¹
1.The University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Groningen, the Netherlands., 2.Isala Zwolle, Department of Urology, Zwolle, the Netherlands.
New Devices, Pelvic Floor, Male

16:45

#217 Exploring pelvic floor muscle activity in male lower urinary tract symptoms

Presenter: Grietje E Knol-de Vries

Vrolijks R¹, Knol-de Vries G¹, Notenboom-Nas F¹, Witte L², Blanker M¹
1.Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen. The Netherlands, 2.Department of Urology, Isala Clinics Zwolle, The Netherlands
Male, Pelvic Floor, Questionnaire

16:52

#218 The relationship among bladder emptying, incident acute urinary retention and all-causes mortality in men having lower urinary tract symptoms

Presenter: Kar Kei Steffi Yuen

YUEN K¹, CHAN C¹, TEOH J¹, YEE C¹, CHIU K¹, LIU A¹, YIP S¹, TAM H², WONG H¹, WONG H¹, CHAN Y¹, MAK S¹, LI K¹, LO K¹, WONG C¹, LEUNG K¹, HOU S¹, NG C¹, NG C¹, LI S³, KWOK S⁴, SAE LO K³
1.SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, 2.SH Ho Urology Centre, The Chinese University of Hong Kong, 3.Prince of Wales Hospital, The Chinese University of Hong Kong, 4.Princes of Wales Hospital, The Chinese University of Hong Kong
Male, Bladder Outlet Obstruction , Benign Prostatic Hyperplasia (BPH), Nocturia, Prospective Study

17:00

#219 Through The Zipper or Pants Down: Does It Change Uroflowmetry Parameters in Males?

Presenter: Muhammet Irfan Dönmez

Dönmez M¹, Kocalar M¹, Sezgin T¹, Bayraktar A¹, Hamarat M¹, Sümer A¹, Sahin E¹, Ünlü M¹, Kocalar M², Gönen M¹
1.Konya Training and Research Hospital, 2.Konya Numune Hospital
Male, Prospective Study, Voiding Dysfunction

17:07

#220 Add-on effects of tadalafil for tamsulosin-treated patients with benign prostatic hyperplasia suffering from residual lower urinary tract symptoms: a randomized, placebo-controlled, double-blind, crossover study

Presenter: Hiromitsu Negoro

Negoro H¹, Goto T¹, Akamatsu S¹, Terada N¹, Kobayashi T¹, Matsui T¹, Yamamoto T², Yonezawa A², Omura T², Matsubara K², Ogawa O¹
1.Department of Urology, Kyoto University Hospital, 2.Department of Clinical Pharmaclology and Therapeutics, Kyoto University Hospital
Benign Prostatic Hyperplasia (BPH), Prospective Study, Voiding Dysfunction

17:15

#221 Tadalafil is sufficiently effective for patients with BPH together with severe CP/CPPS

Presenter: Ippei Hiramatsu

Hiramatsu I¹, Soejima M¹, Yoshiyama A¹, Nagashima Y¹, Ishikawa K¹, Uesaka Y¹, Nozaki T¹, Ogishima T¹, Shirai M¹, Mitsuhashi I¹, Sugimura S¹, Mizuno T¹, Noto K¹, Iwata S¹, Shigeta Y², Takasu J³, Honda S⁴, Horie S⁵, Tsujimura A¹
1.Juntendo university urayasu hospital, 2.Nishi-Funabashi Urology Clinic, 3.Urayasu Central Hospital, 4.YATSU HOKEN HOSPITAL, 5.Juntendo university graduate school of medicine
Benign Prostatic Hyperplasia (BPH), Pain, Pelvic/Perineal, Voiding Dysfunction

17:22

#222 I have a life back - The patient experience of urinary obstruction interventions in the UNBLOCS randomised controlled trial.

Presenter: Nikki Cotterill

Cotterill N¹, Khan R¹, Uren A¹, Abrams P¹, Brookes S², Lane A², Noble S², Page T³, Swami S⁴, Taylor H², Worthington J², Hashim H⁵
1.Bristol Urological Institute, 2.University of Bristol, 3.The Newcastle upon Tyne Hospitals NHS Foundation Trust, 4.NHS Grampian, 5.North Bristol NHS Trust
Bladder Outlet Obstruction , Outcomes Research Methods, Quality of Life (QoL), Male

17:30

#223 Mirabegron vs. placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a safety analysis from the PLUS study

Presenter: Sender Herschorn

Herschorn S¹, McVary K², Cambronero Santos J³, Foley S⁴, Kristy R⁵, Choudhury N⁶, Hairston J⁵, Kaplan S⁷
1.Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 2.Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA, 3.Department of Urology, Infanta Leonor Hospital, Madrid, Spain, 4.Department of Urology, Royal Berkshire Hospital, Reading, UK, 5.Astellas Pharma Global Development Inc., Northbrook, IL, USA, 6.Astellas Pharma Europe Ltd., Chertsey, UK, 7.Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
Benign Prostatic Hyperplasia (BPH), Male, Overactive Bladder, Prospective Study, Clinical Trial

17:37

#224 Changes in lower urinary tract symptoms after more than five years of follow-up in a cohort of prostate cancer treated by permanent iodine-125 implant brachytherapy.

Presenter: Koji Iinuma

Iinuma K¹, Nakano M², Taku K¹, Maekawa Y¹, Horie K¹, Nakane K¹, Tanaka H³, Matsuo M³, Mizutani K¹, Tsuchiya T¹, Koie T¹
1.Department of Urology, Gifu University Graduate school of Medicine, 2.Department of Urology, Gifu prefectural general medical center, 3.Department of Radiology, Gifu University Graduate school of Medicine
Male, Quality of Life (QoL), Prospective Study, Voiding Dysfunction , Overactive Bladder

17:45

#225 Risk factors of pharmacotherapy for storage symptoms after transurethral resection of the prostate in patients with benign prostatic hyperplasia

Presenter: Yu-Hua Fan

Fan Y¹, Tsai C¹, Lin T¹
1.Taipei Veterans General Hospital, Taipei, Taiwan
Benign Prostatic Hyperplasia (BPH), Surgery, Overactive Bladder

17:52

#226 Comparison of long-term effects of tadalafil and silodosin on storage and voiding function in male patients with detrusor underactivity induced by benign prostatic hyperplasia

Presenter: Yoshihisa Matsukawa

Matsukawa Y¹, Takai S¹, Majima T¹, Funahashi Y¹, Yamamoto T¹, Gotoh M¹
1.Nagoya University Graduate School of Medicine, Nagoya, Japan
Detrusor Hypocontractility, Benign Prostatic Hyperplasia (BPH), Underactive Bladder, Voiding Dysfunction , Male

Content Visitors (staff only)

Male Lower Urinary Tract Symptoms 1

Scientific Podium Short Oral Session S11

Session Schedule

Comments

Chat